QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION

• US 20110256092A1
• Filed: 03/14/2011
• Published: 10/20/2011
• Est. Priority Date: 10/12/2007
• Status: Abandoned Application

• Current Assignee: Supergen Incorporated (Otsuka Holdings Company Limited)
• Original Assignee: Supergen Incorporated (Otsuka Holdings Company Limited)
• Inventors: Xu, Yong, Phiasivongsa, Pasit, Swierczek, Krzysztof, Brooke, Darby, Bearss, David J., Vankayalapati, Hariprasad, Redkar, Sanjeev G., Denny, William, Gamage, Swarna
• Application Number:
  US13/047,635
• Publication Number:
  US 20110256092A1
• Time in Patent Office: Days
• US Class Current: 424/85.2
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links

Abstract

Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.

Claims

1. A compound selected from the group consisting of 4-(4-(4-(quinolin-4-ylamino)benzamido)phenylthio)pyrrolidine-2-carboxylic acid;

3-(4-(4-(quinolin-4-ylamino)benzamido)phenylthio)pyrrolidine;

N-(4-(piperidin-4-ylthio)phenyl)-4-(quinolin-4-ylamino)-benzamide; and

N-(4-(piperidin-3-ylthio)phenyl)-4-(quinolin-4-ylamino)-benzamide, or a physiologically acceptable salt thereof.

2. The compound of claim 1, wherein the compound is 4-(4-(4-(quinolin-4-ylamino)benzamido)phenylthio)pyrrolidine-2-carboxylic acid, or a physiologically acceptable salt thereof.

3. The compound of claim 1, wherein the compound is 3-(4-(4-(quinolin-4-ylamino)benzamido)phenylthio)pyrrolidine, or a physiologically acceptable salt thereof.

4. The compound of claim 1, wherein the compound is N-(4-(piperidin-4-ylthio)phenyl)-4-(quinolin-4-ylamino)-benzamide, or a physiologically acceptable salt thereof.

5. The compound of claim 1, wherein the compound is N-(4-(piperidin-3-ylthio)phenyl)-4-(quinolin-4-ylamino)-benzamide, or a physiologically acceptable salt thereof.

6. The compound of claim 1, wherein the physiologically acceptable salt is formed with an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, carboxylic, sulfonic, sulfo or phospho acids, acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid, isonicotinic acid, amino acid, glutamic acid, aspartic acid, phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid, and ascorbic acid.

7. The compound of claim 1, wherein the physiologically acceptable salt is a sodium, calcium, lithium, potassium, ammonium, or trialkylammonium salt.

8. A pharmaceutical composition comprising a compound of claim 1, or a physiologically acceptable salt thereof, and a pharmaceutically-acceptable carrier.

9. The pharmaceutical composition of claim 8, wherein the pharmaceutical composition is in a solid form.

10. The pharmaceutical composition of claim 8, wherein the pharmaceutical composition is in an oral dosage form.

11. The pharmaceutical composition of claim 8, wherein the pharmaceutical composition is in an injectable dosage form.

12. The pharmaceutical composition of claim 8, wherein the pharmaceutical composition is in a topical dosage form.

13. A method for inhibiting DNA methylation in a cell, comprising contacting the cell with a compound of claim 1, or a physiologically acceptable salt thereof, such that DNA methylation activity of the cell is inhibited.

14. A method for inhibiting DNA methylation in a cell, comprising contacting the cell with a compound of claim 1, or a physiologically acceptable salt thereof, such that DNA methyltransferase activity in the cell is inhibited.

15. The method of claim 14, wherein the activity of DNA methyltransferase activity is inhibited via degradation of DNA methyltransferase DNMT1.

16. The method of claim 14, wherein the step of contacting includes contacting the cell with a biologically effective amount of a compound of claim 1, or a physiologically acceptable salt thereof, such that at least 50% of the activity of DNA methyltransferase DNMT1 in the cell is inhibited.

17. The method of claim 14, wherein the step of contacting includes contacting the cell with a biologically effective amount of a compound of claim 1, or a physiologically acceptable salt thereof, such that at least 25% of the activity of DNA methyltransferase DNMT1 in the cell is inhibited.

18. A method for restoring activity of a DNA methylation-suppressed gene in a cell, comprising contacting a cell with a biologically effective amount of a compound of claim 1, or a physiologically acceptable salt thereof, such that activity of the DNA methylation-suppressed gene is elevated by at least 25% relative to that in the absence of the compound or physiologically acceptable salt thereof.

19. The method of claim 18, wherein the step of contacting includes contacting the cell with a biologically effective amount of the compound of claim 1, or a physiologically acceptable salt thereof, such that transcriptional activity or levels of transcript of the DNA-methylation-suppressed gene is elevated by at least 25%.

21. A method for treating a patient suffering from a disease associated with aberrant DNA methylation, comprising administering to the patient the pharmaceutical composition of claim 8.

22. The method of claim 21, wherein the pharmaceutical composition is administered orally, parenterally, topically, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery, subcutaneously, intraadiposally, intraarticularly, or intrathecally.

23. The method of claim 21, wherein the pharmaceutical composition is administered orally.

24. The method of claim 21, further comprising administering to the patient a second therapeutic agent in combination with the pharmaceutical composition.

25. The method of claim 24, wherein the second therapeutic agent is decitabine or azacitidine.

26. The method according to claim 24, wherein the second therapeutic agent is selected from the group consisting of histone deacylase inhibitors, antibiotic agents, alkylating agents, retinoids, hormonal agents, plant-derived agents, biologic agents, interleukins, interferons, cytokines, immuno-modulating agents, and monoclonal antibodies.

27. The method according to claim 26, wherein the histone deacylase inhibitor is selected from the group consisting of trichostatin A, suberoylanilide hydroxamic acid, oxamflatin, suberic bishydroxamic acid, m-carboxy-cinnamic acid bishydroxamic acid, pyroxamide, trapoxin A, apicidin, depsipeptide, N-(2-amimophenyl)-4-[N-(pyridin-3-ylmethoxycarbonyl)aminomethyl]benzamide, butyric acid, phenylbutyrate and arginine butyrate.

28. The method according to claim 21, wherein the disease associated with aberrant DNA methylation is selected from the group consisting of hematological disorders, benign tumor and cancer.

29. The method according to claim 28, wherein the hematological disorder is selected from the group consisting of acute myeloid leukemia, acute promyelocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, myelodysplastic syndromes, and sickle cell anemia.

30. The method according to claim 28, wherein the cancer is selected from group consisting of breast cancer, skin cancer, bone cancer, prostate cancer, liver cancer, lung cancer, non-small cell lung cancer, brain cancer, cancer of the larynx, gall bladder, pancreas, rectum, parathyroid, thyroid, adrenal, neural tissue, head and neck, colon, stomach, bronchi, and kidney cancer, basal cell carcinoma, squamous cell carcinoma of both ulcerating and papillary type, metastatic skin carcinoma, osteo sarcoma, Ewing'"'"'s sarcoma, veticulum cell sarcoma, myeloma, giant cell tumor, small-cell lung tumor, gallstones, islet cell tumor, primary brain tumor, acute and chronic lymphocytic and granulocytic tumors, hairy-cell tumor, adenoma, hyperplasia, medullary carcinoma, pheochromocytoma, mucosal neuronms, intestinal ganglloneuromas, hyperplastic corneal nerve tumor, marfanoid habitus tumor, Wilm'"'"'s tumor, seminoma, ovarian tumor, leiomyomater tumor, cervical dysplasia and in situ carcinoma, neuroblastoma, retinoblastoma, soft tissue sarcoma, malignant carcinoid, topical skin lesion, mycosis fungoide, rhabdomyosarcoma, Kaposi'"'"'s sarcoma, osteogenic sarcoma, malignant hypercalcemia, renal cell tumor, polycythermia vera, adenocarcinoma, glioblastoma multiforma, leukemias, lymphomas, malignant melanomas, and epidermoid carcinomas.

20. The method of claim 20, wherein the DNA methylation-suppressed gene is selected from the group consisting of 14-3-3 Sigma, ABL1 (P1), ABO, APC, AR (Androgen Receptor), BLT1 (Leukotriene B4 Receptor), BRCA1, CALCA (Calcitonin), CASP8 (CASPASE 8), Caveolin 1, CD44, CFTR, COX2, CSPG2 (Versican), CX26 (Connexin 26), Cyclin A1, DBCCR1, ECAD (E-cadherin), Endothelin Receptor B, EPHA3, EPO (Erythropoietin), ER (Estrogen Receptor), FHIT, GPC3 (Glypican 3), GST-pi, H19, H-Cadherin (CDH13), γ

-globin, HIC1, hMLH1, HOXA5, IGF2 (Insulin-Like Growth Factor II), IGFBP7, IRF7, LKB1, LRP-2 (Megalin), MDGI (Mammary-derived growth inhibitor), MDR1, MDR3 (PGY3), MGMT (O6 methyl guanine methyl transferase), MUC2, MYOD1, N33, NEP (Neutral Endopeptidase 24.1)/CALLA, NIS (sodium-iodide symporter gene), P14/ARF, P15 (CDKN2B), P16 (CDKN2A), P27KIP1, p57 KIP2, PAX6, PgR (Progesterone Receptor), RAR-Beta2, RASSF1, RB1 (Retinoblastoma), TERT, TESTIN, TGFBRI, THBS1 (Thrombospondin-1), TIMP3, TLS3 (T-Plastin), Urokinase (uPA), VHL (Von-Hippell Lindau), WT1, and ZO2 (Zona Occludens

     2).